[ad_1]
Abbott Laboratories ABT said that a Food and Drug Administration panel voted in favor of the safety profile of its heart device TriClip.
The medical device company on Tuesday said that the Circulatory System Devices Panel of the Medical Devices Advisory Committee also confirmed the effectiveness and risk/benefit profile of the device to treat people with tricuspid regurgitation.
Tricuspid…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
[ad_2]
Source link